NCT00192764已完成2 期
Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Failure-free survival
研究概览
简要总结
The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •large-cell non-Hodgkin's lymphoma
- •IPI low-intermediate, high-intermediate and high or bulky mediastinum
- •age 18-65
排除标准
- •previous treatment for lymphoma
- •serious concurrent systemic disease
结局指标
主要结局
Failure-free survival
次要结局
- response rate
- toxicity
- overall survival
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell TumorsTesticular NeoplasmsGerm Cell TumorsNCT02161692Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
已完成
2 期
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose ChemotherapyAggressive Non-hodgkin Lymphoma (aNHL)Lymphoma, B-CellLymphoma, T-CellNCT04121507GWT-TUD GmbH60
已完成
2 期
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell TumorsTesticular CancerNCT00936936M.D. Anderson Cancer Center64
终止
3 期
Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)Non-Hodgkin's LymphomaNCT00133302Japan Clinical Oncology Group450
已完成
不适用
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer PatientsBreast NeoplasmsNeoplasm MetastasisNCT01232062Peking University Cancer Hospital & Institute46